Oxalate Levels Linked to Inflammation and Heart Risks in Kidney Disease

Recent scientific research has identified connections between elevated oxalate levels in the body and increased risks of inflammation and cardiovascular complications for individuals with impaired kidney function. These findings highlight patterns observed in both clinical and experimental studies involving kidney disease.

Elevated oxalate in the bloodstream has been associated with systemic inflammation and a higher likelihood of cardiovascular problems, including sudden cardiac death, among patients who have reduced kidney function. Research also indicates that oxalate crystals can activate specific cellular pathways, resulting in the release of inflammatory molecules and further kidney damage.

Experimental studies using mouse models of chronic kidney disease have shown that increased dietary oxalate can lead to systemic inflammation, high blood pressure, and the development of fibrotic tissue in the heart. Additional research involving these models found that introducing the bacterium Oxalobacter formigenes reduced plasma oxalate, decreased kidney inflammation and fibrosis, and lessened abnormal changes in heart structure.

In patients with chronic kidney disease, higher levels of oxalate in urine over a 24-hour period have been linked to a greater risk of disease progression and the development of end-stage renal disease. Elevated plasma oxalate is also hypothesized to contribute to the development of atherosclerosis, abnormal lipid profiles, and systemic inflammation in individuals with end-stage renal disease.

What the numbers show

• Patients in the highest serum oxalate quartile in the German Diabetes Dialysis Study had a 40% higher risk of combined cardiovascular events and a 62% higher risk of sudden cardiac death
• In a pilot cohort, plasma oxalic acid levels at or above 62.9 µmol/L were independently associated with increased cardiovascular disease events
• Higher 24-hour urinary oxalate was associated with a 33% higher risk of chronic kidney disease progression and a 45% higher risk of end-stage renal disease in CKD stages 2–4

Research published in nephrology and physiology journals has detailed how oxalate crystals can stimulate the NLRP3 inflammasome, a component of the immune system, which in turn triggers the release of interleukin-1β and promotes ongoing kidney inflammation. This process is believed to contribute to the worsening of kidney function over time.

Studies in animal models have further demonstrated that dietary oxalate not only increases inflammation but also leads to high blood pressure and structural changes in the heart, such as fibrosis. These findings suggest that oxalate may play a role in both kidney and cardiovascular health in the context of chronic kidney disease.

In experimental settings, colonization with Oxalobacter formigenes in mice with chronic kidney disease resulted in lower plasma oxalate levels and improvements in both kidney and heart tissue health. This suggests that modifying gut bacteria could influence oxalate metabolism and related health outcomes.

Collectively, these studies support an association between oxalate levels and adverse health outcomes in kidney disease, with multiple lines of evidence pointing to both direct inflammatory effects and increased risk of cardiovascular events among affected patients.

* This article is based on publicly available information at the time of writing.